Edition:
United States

Sarepta Therapeutics Inc (SRPT.OQ)

SRPT.OQ on NASDAQ Stock Exchange Global Select Market

75.61USD
10:32am EDT
Change (% chg)

$-0.79 (-1.03%)
Prev Close
$76.40
Open
$76.59
Day's High
$76.59
Day's Low
$74.53
Volume
54,827
Avg. Vol
474,069
52-wk High
$84.35
52-wk Low
$28.82

Latest Key Developments (Source: Significant Developments)

Sarepta Therapeutics Announces Plan To Submit A New Drug Application For Accelerated Approval Of Golodirsen
Monday, 12 Mar 2018 07:30am EDT 

March 12 (Reuters) - Sarepta Therapeutics Inc ::SAREPTA THERAPEUTICS ANNOUNCES PLAN TO SUBMIT A NEW DRUG APPLICATION (NDA) FOR ACCELERATED APPROVAL OF GOLODIRSEN (SRP-4053) IN PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD) AMENABLE TO SKIPPING EXON 53.SAREPTA THERAPEUTICS INC - INTENDS TO COMPLETE A ROLLING SUBMISSION OF A GOLODIRSEN NDA BY YEAR-END 2018.SAREPTA THERAPEUTICS INC - MET WITH FDA DIVISION OF NEUROLOGY PRODUCTS IN FEBRUARY TO OBTAIN GUIDANCE ON REGULATORY PATHWAY FOR GOLODIRSEN.  Full Article

Sarepta Therapeutics Reports Q4 Non-GAAP Loss Per Share $0.28
Thursday, 1 Mar 2018 04:01pm EST 

March 1 (Reuters) - Sarepta Therapeutics Inc ::SAREPTA THERAPEUTICS ANNOUNCES FOURTH QUARTER 2017 AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS.Q4 NON-GAAP LOSS PER SHARE $0.28.Q4 GAAP LOSS PER SHARE $0.37.Q4 REVENUE $57.3 MILLION.Q4 EARNINGS PER SHARE VIEW $-0.32, REVENUE VIEW $56.5 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Sarepta Therapeutics Provides FY 2018 Rev Forecast For Exondys 51
Monday, 8 Jan 2018 01:41pm EST 

Jan 8 (Reuters) - Sarepta Therapeutics Inc ::SAREPTA THERAPEUTICS PRE-ANNOUNCES FOURTH QUARTER 2017 REVENUE AND PROVIDES FULL-YEAR 2018 REVENUE GUIDANCE FOR EXONDYS 51® (ETEPLIRSEN), REPRESENTING APPROXIMATELY 100 PERCENT YEAR-OVER-YEAR GROWTH.Q4 REVENUE $57.3 MILLION VERSUS I/B/E/S VIEW $55.8 MILLION.SEES FY 2018 REVENUE $295 MILLION TO $305 MILLION.SAYS FULL-YEAR 2018 EXONDYS 51 REVENUE GUIDANCE OF $295 - $305 MILLION.SAYS ‍FULL-YEAR 2017 EXONDYS 51 UNAUDITED REVENUE OF $154.6 MILLION​.  Full Article

Capital Ventures International Reports 5.4 Pct Passive Stake In Sarepta Therapeutics
Thursday, 21 Dec 2017 09:22am EST 

Dec 21 (Reuters) - Sarepta Therapeutics Inc ::CAPITAL VENTURES INTERNATIONAL REPORTS A 5.4 PERCENT PASSIVE STAKE IN SAREPTA THERAPEUTICS INC AS OF DECEMBER 11, 2017 - SEC FILING.  Full Article

Sarepta Therapeutics prices $475 million of convertible senior notes due 2024
Wednesday, 8 Nov 2017 07:14pm EST 

Nov 8 (Reuters) - Sarepta Therapeutics Inc :Sarepta Therapeutics prices $475 million of convertible senior notes due 2024.Sarepta Therapeutics-‍priced $475 million aggregate principal amount of convertible senior unsecured notes that will mature on November 15, 2024​.Sarepta Therapeutics - ‍notes will bear cash interest at a rate of 1.50%, payable on May 15 and November 15 of each year, beginning on May 15, 2018​.  Full Article

Sarepta Therapeutics announces proposed offering of $375 mln of convertible senior notes
Tuesday, 7 Nov 2017 04:15pm EST 

Nov 7 (Reuters) - Sarepta Therapeutics Inc :Sarepta Therapeutics announces proposed offering of $375 million of convertible senior notes due 2024.Sarepta Therapeutics Inc - ‍Chief Executive Officer indicates interest in purchasing $2 million of shares of Sarepta's common stock​.Sarepta - ‍intends to use a portion of net proceeds from offering to pay cost of certain capped call transactions​.Sarepta - ‍purchase price/share of stock bought by ingram expected to equal closing price/share of co's stock on date of pricing of offering​.  Full Article

Sarepta Therapeutics reports FDA clearance of IND for co's ppmo exon 51 candidate, srp-5051
Tuesday, 7 Nov 2017 08:30am EST 

Nov 7 (Reuters) - Sarepta Therapeutics Inc ::Sarepta Therapeutics announces FDA clearance of IND for the company's ppmo exon 51 candidate, srp-5051.Sarepta Therapeutics Inc - will immediately initiate its phase 1/2a clinical trial and begin screening patients with dmd amenable to skipping exon 51​.  Full Article

Sarepta Therapeutics says FDA clears gene therapy IND application
Friday, 3 Nov 2017 08:30am EDT 

Nov 3 (Reuters) - Sarepta Therapeutics Inc -:Sarepta Therapeutics and Nationwide Children’S Hospital announce U.S. Food And Drug Administration (FDA) clearance of the IND application for the GALGT2 gene therapy program.Sarepta Therapeutics- ‍IND application for GALGT2 gene therapy program was cleared by FDA​.Sarepta Therapeutics - Nationwide Children's is on track to initiate Phase 1/2A clinical trial in individuals with DMD by year-end 2017 ​.  Full Article

Sarepta Therapeutics signs exclusive global collaboration with Duke University
Tuesday, 31 Oct 2017 08:30am EDT 

Oct 31 (Reuters) - Sarepta Therapeutics Inc :Sarepta Therapeutics signs exclusive global collaboration with Duke University for Gene Editing CRISPR/CAS9 technology to develop new treatments for Duchenne Muscular Dystrophy (DMD).Sarepta Therapeutics Inc - ‍financial terms of agreement have not been disclosed​.  Full Article

Sarepta Therapeutics sees FY17 revenue $150 mln to $155 mln
Wednesday, 25 Oct 2017 04:01pm EDT 

Oct 25 (Reuters) - Sarepta Therapeutics Inc ::Sarepta Therapeutics announces third quarter 2017 financial results and recent corporate developments.Q3 non-GAAP loss per share $0.20.Q3 earnings per share view $-0.85 -- Thomson Reuters I/B/E/S.Q3 GAAP loss per share $0.78.Sees FY 2017 revenue $150 million to $155 million.Q3 revenue $46 million versus I/B/E/S view $40.8 million.Sarepta Therapeutics Inc - ‍raises annual 2017 revenue guidance to between $150 million and $155 million​.  Full Article

Sarepta Therapeutics beats bid to revive shareholder class action

A federal appeals court has upheld the dismissal of a lawsuit accusing Sarepta Therapeutics Inc of misleading shareholders by suggesting it had gathered enough data to seek U.S. Food and Drug Administration approval in 2014 to market a treatment for a rare muscle disorder.